Table 2.
Plasma-derived PK parameters of the XBLJ-13 and nintedanib.
| Property | XBLJ-13 | Nintedanib |
|---|---|---|
| Concentration (mg/kg) | 10 | 50 |
| MRTINF_obs (h) | 4.42 ± 0.57 | 5.19 |
| AUCINF_obs (h·ng/mL) | 4467 ± 516 | 2720 |
| AUClast (h·ng/mL) | 4451 ± 522 | NA |
| Cmax (ng/mL) | 986 ± 161 | 547 |
| Tmax (h) | 2.00 ± 00 | N/A |
| T1/2 (h) | 2.88 ± 0.32 | 5.15 |
aFormulation: DMAC/0.5% methylcellulose (5:95, v/v); AUC = area under the curve; Cmax = maximal concentration; MRT = mean residence time; NA = not applicable; T1/2 = half-life; only representative PK data are listed here. Linear dose dependency and no sex effect was observed.